HONG KONG, June 17, 2024 /PRNewswire/ -- Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutic and neurointerventional procedural medical device markets, announced the publication of its audited financial results for the year ended December 31, 2023 ("the period") on June 16, 2024. Additionally, the Company announced that it would resume trading on the Hong Kong Stock Exchange on June 17, 2024. "We are pleased to be reporting an exceptional year for Peijia and are eager for our investors to have access to the public markets once again," said Dr. Yi Zhang, Chairman and CEO of Peijia Medical. "The preliminary, unaudited results published on March 28, 2024 remain unchanged following the audit, reiterating revenue growth of 75.9% and significant increases to our operational efficiencies. Our success was driven by market share gains, product portfolio expansion and key strategic partnerships. I'm very proud of our team and all that we were able to accomplish in 2023 and look forward to leveraging that momentum for the remainder of 2024." On March 28, 2024, Peijia announced a delay in the filing of the Company's 2023 Annual Report as a result of the auditor's work on certain financial assets, specifically related to the valuation of a prior HK$80million investment by the Company. On April 2, 2024, trading in Peijia shares was suspended pending publication of audited results. According to the Company's announcement on June 16, 2024, the audit of the 2023 Annual Results have been completed in accordance with International Standards on Auditing issued by the International Auditing and Assurance Standards Board and the Company's auditor, PricewaterhouseCoopers, have expressed unqualified opinion in the independent auditor's report. Trading resumed on June 17, 2024. Financial Highlights During ...